Product Catalog

Clorox Healthcare
Nasal Antiseptic Swabs

Featured in the Wall Street Journal article The Ultimate Battle Against MRSA

Decolonize the nose without the risk and complexity of antibiotics1

Clorox Healthcare™ Nasal Antiseptic Swabs
 

Quick Facts

Non-Irritating Antiseptic Alternative for Nasal Decolonization

 

  • Safety: Clinically shown to be non-irritating and
    well tolerated in the nares after 10 applications3
  • Efficacy: Reduces 99.4% of S. aureus at 1 hour
    and maintains persistence through 12 hours2
  • Acceptability: Determined by patients to be
    both comfortable during application and an
    overall positive use experience
  • 96% of participants experienced no discomfort throughout product application, with 87% considering application to be comfortable or extremely comfortable3

  • 96% of participants were satisfied with the overall nasal decolonization experience, with 83% considering it to be a good to excellent experience3

No Evidence of Bacterial Resistance

 

  • Nasal decolonization with antibiotics may contribute to bacterial resistance
  • There is growing evidence of resistance of S. aureus and MRSA to mupirocin. High-level resistance has been associated with nasal decolonization failure4
  • The CDC notes that antibiotic stewardship, the commitment to use antibiotics only when necessary to treat or prevent disease, is the single most important action needed to greatly slow down the development and spread of antibiotic-resistant infections5
 
  • Studies have not shown that bacteria develop resistance to povidone-iodine antiseptic6,7
  • Use of antiseptic instead of antibiotic for nasal decolonization enables antibiotic stewardship

Simple & Easy to Use

 

  • Presaturated, ready-to-use swabs simplify application
  • Applied by healthcare provider one hour before surgery, increasing likelihood of compliance

Inexpensive Decolonization Method

 

  • Cost-effective decolonization method
  • Decolonize the nose for less than the cost to screen for S. aureus8
  1. "Risk" refers to growing evidence of resistance of S. aureus and MRSA to mupirocin; "complexity" refers to the five-day, twice-daily application protocol of mupirocin.
  2. Reduces 99.4% of S. aureus at 1 hour and maintains persistence through 12 hours (shown in in vitro Clorox Study #9550-005).
  3. The Clorox Services Company Study Number: 2015-002/2015-003
  4. Hetem DJ, Bonten MJ. "Clinical Relevance of Mupirocin Resistance in Staphylococcus aureus." Journal of Hospital Infection. 2013 Dec;85(4):249-56.
  5. "Antibiotic Resistance Threats in the United States, 2013." U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. http://www.cdc.gov/drugresistance/threat-report-2013/index.html.
  6. Houang ET et al. "Absence of Bacterial Resistance to Povidone Iodine." Journal of Clinical Pathology. 1976 Aug;29(8):752-5.
  7. Lanker, Klossner B et al. "Nondevelopment of Resistance by Bacteria During Hospital Use of Povidone-Iodine." Dermatology. 1997;195 Suppl 2:10-3.
  8. Huang SS et al. "Cost Savings of Universal Decolonization to Prevent Intensive Care Unit Infection: Implications of the REDUCE MRSA Trial." Infection Control & Hospital Epidemiology. 2014 Oct;35 Suppl 3:S23-31.

How to Order

Contact us at healthcare@clorox.com
or call 1-800-234-7700.

Sign Up for News

Receive industry insights, toolkits or product sample offers right in your inbox!

Subscribe Today

close